Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy

Br J Haematol. 2022 Jan;196(2):360-362. doi: 10.1111/bjh.17818. Epub 2021 Sep 2.
No abstract available

Keywords: BNT162b2; CAR-T cells; COVID 19; SARS-CoV-2 mRNA; vaccine.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Viral / biosynthesis*
  • Antigens, Viral / immunology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • BNT162 Vaccine / adverse effects
  • BNT162 Vaccine / immunology*
  • Biological Products / therapeutic use
  • COVID-19 / prevention & control*
  • Combined Modality Therapy
  • Female
  • Fever / etiology
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunization, Secondary
  • Immunocompromised Host
  • Immunogenicity, Vaccine
  • Immunoglobulin G / biosynthesis*
  • Immunotherapy, Adoptive*
  • Lymphoma, Non-Hodgkin / immunology
  • Lymphoma, Non-Hodgkin / therapy
  • Male
  • Middle Aged
  • Pain / etiology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Receptors, Antigen, T-Cell / therapeutic use
  • Receptors, Chimeric Antigen / therapeutic use
  • SARS-CoV-2 / immunology*
  • Spike Glycoprotein, Coronavirus / immunology
  • Vaccination
  • Young Adult

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • Biological Products
  • Immunoglobulin G
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • brexucabtagene autoleucel
  • BNT162 Vaccine
  • tisagenlecleucel
  • axicabtagene ciloleucel